Compass Pathways (CMPS) — Compass Pathways announced publication of an open-label Phase 2 study of a single 25 mg dose of its synthetic psilocybin candidate COMP360 in 22 patients with PTSD.
The data showed COMP360 was well tolerated with rapid and durable symptom improvement out to 12 weeks after a single dose. The findings support a potential second indication beyond treatment-resistant depression, where Compass reported positive Phase 3 topline results earlier in 2025.
Source: ir.compasspathways.com
For the rest of that week's sector news, read our week in review.